Ennaid Therapeutics | LSU grad files for patent, working with FDA on drug to stop COVID-19
19535
post-template-default,single,single-post,postid-19535,single-format-standard,ajax_fade,page_not_loaded,,qode-theme-ver-7.7,wpb-js-composer js-comp-ver-6.4.2,vc_non_responsive

LSU grad files for patent, working with FDA on drug to stop COVID-19

07 Apr LSU grad files for patent, working with FDA on drug to stop COVID-19

April 06, 2020 6:50 PM in NewsSource: WBRZBy: Chris Nakamoto

ATLANTA – A Baton Rouge native and LSU grad said scientists working for her company have found a drug that is showing promise in laboratories at blocking the continued spread of COVID-19.

Darnisha Harrison went to Baton Rouge High and LSU before moving to Georgia. She is the CEO and founder of Ennaid Therapeutics, a pharmaceutical company that develops antiviral drugs. Two weeks ago, she said a patent was filed after scientists discovered a drug showed strong scientific evidence of blocking two proteins that cause COVID-19 from invading healthy host cells and replicating.

The drug is called ENU200 and was previously approved by the FDA for other conditions. The drug is now a repurposed drug and is no longer prescribed.

Read the rest of the story on abc’s WBRZ2 website HERE

Tags:
No Comments

Post A Comment